Index
-
Market Cap
7.64B
Enterprise Value
12.29B
Income
-111.00M
Sales
5.42B
Book/sh
18.02
Cash/sh
1.44
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
13000
IPO
May 06, 2022
P/E
-
Forward P/E
18.01
PEG
0.41
P/S
1.41
P/B
1.19
P/C
14.83
P/FCF
30.34
EV/EBITDA
13.45
EV/Sales
2.27
Quick Ratio
1.04
Current Ratio
1.56
Debt/Eq
0.79
LT Debt/Eq
0.78
Option/Short
Yes / Yes
EPS (ttm)
-0.31
EPS next Y
1.19
EPS next Q
0.37
EPS this Y
83.70%
EPS next Y
26.69%
EPS next 5Y
43.70%
EPS past 3/5Y
- -
Sales past 3/5Y
10.62% 8.38%
EPS Y/Y TTM
63.73%
Sales Y/Y TTM
8.88%
EPS Q/Q
212.03%
Sales Q/Q
7.34%
Insider Own
88.79%
Insider Trans
-0.06%
Inst Own
10.10%
Inst Trans
-0.44%
ROA
-0.80%
ROE
-1.73%
ROIC
-0.97%
Gross Margin
58.36%
Oper. Margin
9.41%
Profit Margin
-2.05%
SMA20
14.37%
SMA50
20.12%
SMA200
27.30%
Trades
Shs Outstand
357.39M
Shs Float
40.09M
52W High
21.36 0.05%
52W Low
14.44 47.99%
Volatility
3.65% 3.69%
ATR (14)
0.71
RSI (14)
75.18
Beta
0.51
Rel Volume
2.49
Avg Volume
604.09K
Volume
1,502,278
Perf Week
6.69%
Perf Month
32.98%
Perf Quarter
27.51%
Perf Half Y
33.31%
Perf YTD
25.12%
Perf Year
33.81%
Perf 3Y
33.23%
Perf 5Y
-
Perf 10Y
-
Prev Close
20.96
Price
21.37
Change %
1.96%
Analysts 12 incl. previous ratings
Rating Distribution 6 Buy · 6 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Nov 02, 2026 Downgrade H H.C. Wainwright
Buy → Neutral $22 +2.9% Oct 07, 2026 Initiated B Barclays
Overweight $24 +12.3% Sep 09, 2026 Initiated L Leerink Partners
Outperform $24 +12.3% Jul 28, 2026 Initiated U UBS
Buy $21 -1.7% Jan 05, 2026 Downgrade E Evercore ISI
Outperform → In-line $18 -15.8% Dec 11, 2025 Upgrade C Citigroup
Neutral → Buy $20 -6.4% Dec 02, 2025 Upgrade M Morgan Stanley
Equal-Weight → Overweight $21 -1.7% Oct 01, 2025 Initiated G Goldman
Neutral $16 -25.1% May 02, 2025 Reiterated H H.C. Wainwright
Buy $20 → $15 -29.8% Mar 28, 2025 Downgrade W Wells Fargo
Overweight → Equal Weight $24 → $15 -29.8% Dec 11, 2024 Downgrade C Citigroup
Buy → Neutral $24 → $22 +2.9% Dec 02, 2024 Downgrade M Morgan Stanley
Overweight → Equal-Weight $19 -11.1% Oct 15, 2024 Upgrade E Evercore ISI
In-line → Outperform $19 → $25 +17.0% Jul 10, 2024 Initiated R Raymond James
Outperform $19 -11.1% May 06, 2024 Upgrade M Morgan Stanley
Equal-Weight → Overweight $16 → $18 -15.8% Jan 04, 2024 Downgrade E Evercore ISI
Outperform → In-line $19 → $17 -20.4% Dec 12, 2023 Initiated S Stifel
Hold $16 -25.1% Oct 03, 2023 Resumed E Evercore ISI
Outperform $20 -6.4% May 30, 2023 Resumed M Morgan Stanley
Equal-Weight $20 -6.4% Mar 09, 2023 Initiated N Needham
Hold
Show Previous Ratings
Oct-29-26 07:00AM
Oct-28-26 05:05PM
02:36PM
10:51AM
06:58AM
08:09AM
Loading…
Oct-12-26 08:09AM
06:45AM
Oct-07-26 10:00AM
Oct-06-26 04:30PM
Oct-05-26 07:30AM
Sep-11-26 06:11AM
Sep-02-26 07:00AM
Sep-01-26 06:58AM
Aug-26-26 06:11AM
Aug-24-26 04:30PM
02:30AM
Loading…
Aug-07-26 02:30AM
Aug-06-26 07:04AM
07:00AM
Jul-29-26 03:01PM
07:06AM
06:58AM
Jul-16-26 07:00AM
Jul-09-26 07:10PM
04:30PM
07:00AM
Jul-06-26 07:15AM
Jul-01-26 07:00AM
Jun-10-26 06:00AM
05:12AM
Jun-01-26 06:59AM
07:15AM
Loading…
May-21-26 07:15AM
May-20-26 04:49PM
May-19-26 07:00AM
May-07-26 07:00AM
May-06-26 07:15AM
Apr-30-26 07:00AM
03:18AM
Apr-29-26 07:07AM
06:58AM
Apr-23-26 07:00AM
Apr-22-26 07:15AM
Apr-16-26 07:00AM
Apr-08-26 07:00AM
Apr-07-26 07:00AM
Apr-06-26 07:00AM
Mar-30-26 07:15AM
Mar-23-26 07:00AM
Mar-11-26 06:00AM
Mar-09-26 07:15AM
Feb-27-26 12:57PM
05:14AM
Feb-25-26 12:36AM
Feb-24-26 07:00AM
Feb-19-26 12:00PM
12:31AM
Feb-18-26 10:11PM
02:58PM
02:23PM
02:00PM
01:25PM
01:25PM
09:36AM
09:30AM
08:10AM
07:37AM
07:19AM
(Associated Press Finance)
06:58AM
Feb-16-26 10:07PM
09:15AM
Feb-12-26 08:50AM
Feb-11-26 09:30AM
Feb-09-26 11:02PM
11:40AM
Jan-29-26 11:34PM
Jan-23-26 11:40AM
Jan-20-26 07:15AM
Jan-05-26 07:00AM
Jan-02-26 04:30PM
Dec-23-25 07:30AM
Dec-17-25 04:30PM
Dec-12-25 04:48PM
Dec-11-25 11:41AM
Dec-04-25 10:09PM
Dec-02-25 11:10AM
Nov-18-25 04:30PM
Nov-13-25 02:57PM
(Morningstar Research)
-5.48%
08:55AM
08:41AM
Nov-10-25 06:59AM
04:28AM
Nov-05-25 12:35AM
Nov-03-25 04:30PM
Oct-30-25 01:34AM
Oct-29-25 03:47PM
09:30AM
08:05AM
07:23AM
07:06AM
(Associated Press Finance)
06:58AM
Oct-28-25 09:26AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bernier Nathalie D. Former Director Nov 03 '26 Proposed Sale 19.88 40,022 795,735 Nov 03 11:29 AM Munsch Frederick SVP, Controller and CAO Oct 29 '26 Option Exercise 17.99 112,015 2,015,306 157,846 Nov 02 05:05 PM Munsch Frederick SVP, Controller and CAO Oct 29 '26 Sale 20.48 112,015 2,294,067 45,831 Nov 02 05:05 PM Munsch Frederick Officer Oct 29 '26 Proposed Sale 20.48 112,015 2,294,349 Oct 29 04:25 PM Ling Karen Former Director Sep 28 '26 Proposed Sale 16.83 4,500 75,735 Sep 28 03:10 PM Munsch Frederick SVP, Controller and CAO Aug 10 '26 Sale 16.78 52,900 887,662 45,831 Aug 12 07:06 PM VON ESCHENBACH ANDREW C. Director Aug 06 '26 Sale 16.50 12,500 206,250 69,792 Aug 10 08:57 PM VON ESCHENBACH ANDREW C. Director Aug 07 '26 Sale 16.58 6,059 100,458 63,733 Aug 10 08:57 PM Munsch Frederick Former Officer Aug 10 '26 Proposed Sale 16.78 52,900 887,885 Aug 10 04:58 PM VON ESCHENBACH ANDREW C. Former Director Aug 07 '26 Proposed Sale 16.58 6,059 100,430 Aug 07 05:43 PM VON ESCHENBACH ANDREW C. Former Director Aug 06 '26 Proposed Sale 16.50 12,500 206,193 Aug 06 03:11 PM Bailey A Robert D EVP & Chief Legal Officer Mar 06 '26 Buy 17.15 14,600 250,332 231,890 Mar 10 05:23 PM Eldessouky Sam EVP and CFO Mar 06 '26 Buy 17.13 4,000 68,520 403,130 Mar 10 04:34 PM SAUNDERS BRENT L CEO and Chairman of the Board Mar 06 '26 Buy 17.14 14,700 251,958 966,575 Mar 10 04:32 PM Ross Thomas W. Sr. Director Mar 03 '26 Buy 17.68 4,500 79,556 64,891 Mar 04 04:18 PM Alfonso Eduardo Director Mar 02 '26 Buy 17.90 4,300 76,970 9,555 Mar 03 04:26 PM VON ESCHENBACH ANDREW C. Director Feb 27 '26 Buy 18.30 4,364 79,883 66,450 Mar 03 04:24 PM COLLIS STEVEN H Director Feb 23 '26 Buy 17.81 15,000 267,150 20,255 Feb 24 04:23 PM ROBERTSON RUSSEL C Director Feb 20 '26 Buy 17.90 4,400 78,760 72,407 Feb 24 04:16 PM Ling Karen Director Feb 19 '26 Buy 17.74 4,000 70,968 41,676 Feb 23 04:20 PM
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
Executive VP & CFO Mr. Osama A. Eldessouky
Executive VP & Chief Legal Officer Mr. A. Robert D. Bailey
Ph.D. Dr. Yehia Hashad M.D.
President of Global Pharmaceuticals & International Consumer Mr. Andrew J. Stewart
Interim CEO & Chairman of the Board Mr. Thomas J. Appio